Template:ICH Treatment: Difference between revisions
(Convert BP control, TXA, and desmopressin dosing to MedicationDose templates for SMW integration)
 
(One intermediate revision by one other user not shown)
Line 17: Line 17:




*[[Nicardipine]] in ICH: Start at 5mg/hr, increase 2.5mg q5min until the target blood pressure is achieved and then immediately titrate down to maintenance infusion of 3mg/hr.
*{{MedicationDose|drug=Nicardipine|dose=5-15 mg/hr IV, titrate by 2.5 mg q5min|route=IV drip|context=BP control in ICH|indication={{PAGENAME}}|population=Adult|notes=Titrate down to 3 mg/hr maintenance once target achieved}}
*[[Labetalol]] in ICH: 20mg bolus over 1-2 minutes, repeat q3-5 mins until target blood pressure is achieved and then start an infusion of 1-8mg/min.
*{{MedicationDose|drug=Labetalol|dose=20 mg IV bolus, repeat q3-5 min; then 1-8 mg/min drip|route=IV|context=BP control in ICH|indication={{PAGENAME}}|population=Adult}}


===Reverse coagulopathy===
===Reverse coagulopathy===
[[File:Harobr tICH algorithm.png|thumb|Example coagulopathy reversal algorithm.]]
[[File:Harobr tICH algorithm.png|thumb|Example ''traumatic'' ICH coagulopathy reversal algorithm.]]
*See [[anticoagulant reversal for life-threatening bleeds]] if on a known anticoagulant (e.g. [[heparin]], [[coumadin]], [[rivaroxaban]])
*See [[anticoagulant reversal for life-threatening bleeds]] if on a known anticoagulant (e.g. [[heparin]], [[coumadin]], [[rivaroxaban]])
*[[Tranexamic acid]] 1g (if within 3 hours of event), followed by an additional 1g infused over 8 hours <ref>[[EBQ:CRASH-3 Trial|Crash-3 Trial]]</ref>
*{{MedicationDose|drug=Tranexamic acid|dose=1g IV (within 3 hrs of event), then 1g over 8 hrs|route=IV|context=Coagulopathy reversal in ICH|indication={{PAGENAME}}|population=Adult}} <ref>[[EBQ:CRASH-3 Trial|Crash-3 Trial]]</ref>


====Antiplatelet Reversal====
====Antiplatelet Reversal====
''Includes [[aspirin]], [[prasugrel]], [[clopidogrel]]''
''Includes [[aspirin]], [[prasugrel]], [[clopidogrel]]''
*Consider [[desmopressin]] (0.3mcg/kg)
*Consider {{MedicationDose|drug=Desmopressin|dose=0.3 mcg/kg IV|route=IV|context=Antiplatelet reversal in ICH|indication={{PAGENAME}}|population=Adult}}
*Platelet transfusion
*Platelet transfusion
**No known thrombocytopenia: ''increases'' mortality; do '''NOT''' give<ref>[[EBQ:Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomized, open-label, phase 3 trial|(PATCH trial)]]</ref>
**No known thrombocytopenia: ''increases'' mortality; do '''NOT''' give<ref>[[EBQ:Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomized, open-label, phase 3 trial|(PATCH trial)]]</ref>
**Known or diagnosed thrombocytopenia: consider if platelets <50,000
**Known or diagnosed thrombocytopenia: consider if platelets <50,000
***Some hematologists and neurosurgeons recommend for <100,000, despite lack of evidence for improved outcomes
***Some hematologists and neurosurgeons recommend for <100,000, despite lack of evidence for improved outcomes

Latest revision as of 22:32, 20 March 2026

Elevating head of bed

  • 30 degree elevation will help decrease ICP by increasing venous outflow[1]

Seizure Prophylaxis and Treatment

  • Prophylactic antiepileptics not recommended[2]
  • Continuous EEG monitoring probably indicated in ICH patients with depressed mental status that is out of proportion fo degree of brain injury[3]
  • Antiepileptics indicated for clinical seizures or seizures on EEG in patients with altered mental status[4]

Blood Pressure

  • Rapid SBP lowering <140 has been advocated with early research showing improved functional outcome[5], but more recent work has found no difference between SBP <140 and <180[6]
  • SBP >200 or MAP >150
    • Consider aggressive reduction w/ continuous IV infusion
  • SBP >180 or MAP >130 and evidence or suspicion of elevated ICP
    • Consider reducing BP using intermittent or continuous IV meds to keep CPP >60-80
  • SBP >180 or MAP >130 and NO evidence or suspicion of elevated ICP
    • Consider modest reduction of BP (e.g. MAP of 110 or target BP of 160/90)


  • Nicardipine 5-15 mg/hr IV, titrate by 2.5 mg q5min IV drip — Titrate down to 3 mg/hr maintenance once target achieved
  • Labetalol 20 mg IV bolus, repeat q3-5 min; then 1-8 mg/min drip IV

Reverse coagulopathy

Example traumatic ICH coagulopathy reversal algorithm.

Antiplatelet Reversal

Includes aspirin, prasugrel, clopidogrel

  • Consider Desmopressin 0.3 mcg/kg IV IV
  • Platelet transfusion
    • No known thrombocytopenia: increases mortality; do NOT give[8]
    • Known or diagnosed thrombocytopenia: consider if platelets <50,000
      • Some hematologists and neurosurgeons recommend for <100,000, despite lack of evidence for improved outcomes
  1. ↑ http://stroke.ahajournals.org/content/38/6/2001.full
  2. ↑ AHA/ASA Guidelines for the Management of Spontaneous Intracerebral Hemorrhage 2015
  3. ↑ AHA/ASA Guidelines for the Management of Spontaneous Intracerebral Hemorrhage 2015
  4. ↑ AHA/ASA Guidelines for the Management of Spontaneous Intracerebral Hemorrhage 2015
  5. ↑ Anderson CS, Heeley E, Huang Y, et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med. 2013; 368:2355-2365.
  6. ↑ Qureshi AI, Palesch YY, Barsan WG, et al. Intensive Blood-Pressure Lowering in Patients with Acute Cerebral Hemorrhage. N Engl J Med. 2016; 1-11. [Epub ahead of print].
  7. ↑ Crash-3 Trial
  8. ↑ (PATCH trial)
Retrieved from "https://www.wikem.org/w/index.php?title=Template:ICH_Treatment&oldid=387559"